Concepts (271)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis C, Chronic | 21 | 2022 | 86 | 7.510 |
Why?
|
| Antiviral Agents | 20 | 2021 | 211 | 6.160 |
Why?
|
| Hepacivirus | 17 | 2022 | 90 | 3.670 |
Why?
|
| Ribavirin | 13 | 2020 | 27 | 3.610 |
Why?
|
| HIV Infections | 18 | 2022 | 791 | 2.490 |
Why?
|
| Sofosbuvir | 14 | 2020 | 16 | 2.340 |
Why?
|
| Interferons | 7 | 2021 | 36 | 2.250 |
Why?
|
| Hepatitis C | 9 | 2022 | 114 | 2.200 |
Why?
|
| Uridine Monophosphate | 8 | 2015 | 9 | 1.960 |
Why?
|
| Liver | 5 | 2021 | 1118 | 1.510 |
Why?
|
| Hepatitis B, Chronic | 2 | 2021 | 19 | 1.470 |
Why?
|
| Hepatitis B | 2 | 2021 | 42 | 1.460 |
Why?
|
| Liver Cirrhosis | 5 | 2021 | 301 | 1.410 |
Why?
|
| Coinfection | 4 | 2017 | 30 | 1.290 |
Why?
|
| HIV-1 | 8 | 2015 | 177 | 1.230 |
Why?
|
| Genotype | 9 | 2020 | 786 | 1.130 |
Why?
|
| Hepatitis B virus | 2 | 2021 | 23 | 0.950 |
Why?
|
| Interleukins | 5 | 2020 | 79 | 0.920 |
Why?
|
| Sustained Virologic Response | 3 | 2018 | 11 | 0.850 |
Why?
|
| Viral Load | 11 | 2020 | 127 | 0.820 |
Why?
|
| Virus Replication | 8 | 2015 | 104 | 0.780 |
Why?
|
| Drug Therapy, Combination | 10 | 2020 | 649 | 0.770 |
Why?
|
| Substance-Related Disorders | 2 | 2022 | 1242 | 0.740 |
Why?
|
| Proteome | 1 | 2021 | 87 | 0.740 |
Why?
|
| Humans | 47 | 2022 | 68618 | 0.650 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2017 | 151 | 0.640 |
Why?
|
| Chemokine CXCL10 | 2 | 2015 | 21 | 0.640 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2019 | 92 | 0.630 |
Why?
|
| Thymus Gland | 4 | 2006 | 97 | 0.620 |
Why?
|
| CD4-Positive T-Lymphocytes | 5 | 2020 | 226 | 0.600 |
Why?
|
| Babesia | 1 | 2017 | 5 | 0.600 |
Why?
|
| MicroRNAs | 2 | 2020 | 447 | 0.590 |
Why?
|
| Babesiosis | 1 | 2017 | 9 | 0.590 |
Why?
|
| Lipid Metabolism | 2 | 2016 | 186 | 0.580 |
Why?
|
| Fluorenes | 6 | 2015 | 19 | 0.570 |
Why?
|
| Liver Neoplasms | 1 | 2020 | 334 | 0.540 |
Why?
|
| Blood Transfusion | 1 | 2017 | 205 | 0.530 |
Why?
|
| Benzimidazoles | 6 | 2015 | 128 | 0.520 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2015 | 15 | 0.510 |
Why?
|
| Recurrence | 6 | 2020 | 948 | 0.510 |
Why?
|
| Silymarin | 1 | 2015 | 7 | 0.500 |
Why?
|
| Opioid-Related Disorders | 1 | 2019 | 298 | 0.490 |
Why?
|
| Viral Envelope Proteins | 2 | 2005 | 43 | 0.490 |
Why?
|
| Gene Expression Profiling | 2 | 2016 | 498 | 0.480 |
Why?
|
| Liver Transplantation | 1 | 2017 | 400 | 0.460 |
Why?
|
| Treatment Outcome | 11 | 2020 | 7029 | 0.440 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2015 | 284 | 0.440 |
Why?
|
| Microsporidia | 1 | 2012 | 1 | 0.420 |
Why?
|
| Microsporidiosis | 1 | 2012 | 2 | 0.420 |
Why?
|
| Disease Progression | 5 | 2018 | 1038 | 0.410 |
Why?
|
| Immunocompromised Host | 1 | 2012 | 55 | 0.410 |
Why?
|
| Hepatocytes | 3 | 2021 | 205 | 0.410 |
Why?
|
| Stem Cell Transplantation | 1 | 2012 | 58 | 0.410 |
Why?
|
| Hospitalization | 1 | 2018 | 978 | 0.410 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 786 | 0.360 |
Why?
|
| HIV Envelope Protein gp41 | 3 | 2009 | 3 | 0.350 |
Why?
|
| Female | 22 | 2020 | 38074 | 0.340 |
Why?
|
| Middle Aged | 20 | 2018 | 21147 | 0.340 |
Why?
|
| RNA, Viral | 5 | 2015 | 93 | 0.330 |
Why?
|
| Male | 22 | 2020 | 37321 | 0.330 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2020 | 73 | 0.320 |
Why?
|
| Academic Medical Centers | 2 | 2022 | 281 | 0.310 |
Why?
|
| Immunoglobulin G | 2 | 2022 | 481 | 0.290 |
Why?
|
| Pyrophosphatases | 2 | 2016 | 6 | 0.280 |
Why?
|
| Receptors, CXCR4 | 2 | 2009 | 48 | 0.270 |
Why?
|
| CD4 Antigens | 3 | 2017 | 42 | 0.270 |
Why?
|
| Adult | 13 | 2019 | 21403 | 0.270 |
Why?
|
| Retrospective Studies | 6 | 2022 | 7277 | 0.260 |
Why?
|
| Fibrosis | 2 | 2018 | 371 | 0.260 |
Why?
|
| Membrane Fusion | 1 | 2005 | 7 | 0.260 |
Why?
|
| Antibodies, Viral | 3 | 2022 | 110 | 0.260 |
Why?
|
| Quinolines | 4 | 2015 | 48 | 0.250 |
Why?
|
| Interferon-alpha | 2 | 2016 | 46 | 0.250 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2020 | 98 | 0.250 |
Why?
|
| B-Lymphocytes | 3 | 2015 | 329 | 0.240 |
Why?
|
| Anti-HIV Agents | 2 | 2020 | 135 | 0.220 |
Why?
|
| HIV | 2 | 2020 | 56 | 0.220 |
Why?
|
| Killer Cells, Natural | 2 | 2020 | 94 | 0.220 |
Why?
|
| Referral and Consultation | 2 | 2022 | 383 | 0.210 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2020 | 627 | 0.210 |
Why?
|
| Cardiologists | 1 | 2022 | 9 | 0.210 |
Why?
|
| T-Lymphocytes | 3 | 2020 | 597 | 0.210 |
Why?
|
| Cardiovascular Diseases | 3 | 2020 | 940 | 0.210 |
Why?
|
| Seroepidemiologic Studies | 1 | 2022 | 41 | 0.200 |
Why?
|
| South Carolina | 2 | 2019 | 2752 | 0.200 |
Why?
|
| Phenotype | 4 | 2016 | 947 | 0.200 |
Why?
|
| Apoptosis | 2 | 2015 | 1641 | 0.190 |
Why?
|
| Furans | 3 | 2015 | 27 | 0.190 |
Why?
|
| RNA, Messenger | 2 | 2016 | 1664 | 0.190 |
Why?
|
| Thiophenes | 3 | 2015 | 76 | 0.180 |
Why?
|
| Organ Culture Techniques | 3 | 2006 | 122 | 0.180 |
Why?
|
| Immunity, Innate | 1 | 2021 | 156 | 0.180 |
Why?
|
| Social Marginalization | 1 | 2020 | 1 | 0.180 |
Why?
|
| HIV Long-Term Survivors | 1 | 2020 | 2 | 0.180 |
Why?
|
| Longitudinal Studies | 2 | 2020 | 1054 | 0.170 |
Why?
|
| Neutrophils | 1 | 2020 | 204 | 0.170 |
Why?
|
| Vulnerable Populations | 1 | 2020 | 84 | 0.170 |
Why?
|
| Preventive Health Services | 1 | 2020 | 86 | 0.170 |
Why?
|
| Transcriptome | 1 | 2020 | 164 | 0.170 |
Why?
|
| Parenchymal Tissue | 1 | 2018 | 4 | 0.160 |
Why?
|
| Health Personnel | 1 | 2022 | 286 | 0.160 |
Why?
|
| Prognosis | 4 | 2020 | 2093 | 0.160 |
Why?
|
| Kupffer Cells | 1 | 2018 | 75 | 0.160 |
Why?
|
| Dysbiosis | 1 | 2018 | 24 | 0.160 |
Why?
|
| Endopeptidases | 2 | 2017 | 52 | 0.160 |
Why?
|
| Ubiquitin Thiolesterase | 2 | 2017 | 24 | 0.160 |
Why?
|
| Respirovirus Infections | 1 | 2017 | 1 | 0.150 |
Why?
|
| Sendai virus | 1 | 2017 | 2 | 0.150 |
Why?
|
| Exchange Transfusion, Whole Blood | 1 | 2017 | 13 | 0.150 |
Why?
|
| Clindamycin | 1 | 2017 | 25 | 0.150 |
Why?
|
| Quinidine | 1 | 2017 | 15 | 0.150 |
Why?
|
| Blood Donors | 1 | 2017 | 18 | 0.150 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2017 | 17 | 0.150 |
Why?
|
| Ambulatory Care Facilities | 1 | 2018 | 91 | 0.150 |
Why?
|
| Amino Acid Oxidoreductases | 1 | 2017 | 10 | 0.150 |
Why?
|
| Antimalarials | 1 | 2017 | 71 | 0.140 |
Why?
|
| Purines | 1 | 2016 | 39 | 0.140 |
Why?
|
| Biopsy | 1 | 2018 | 540 | 0.140 |
Why?
|
| Alleles | 1 | 2017 | 386 | 0.140 |
Why?
|
| Portal Pressure | 1 | 2016 | 9 | 0.140 |
Why?
|
| Hypertension, Portal | 1 | 2017 | 53 | 0.140 |
Why?
|
| Pharmacogenomic Variants | 1 | 2016 | 15 | 0.140 |
Why?
|
| Transforming Growth Factor beta3 | 1 | 2016 | 16 | 0.140 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2018 | 266 | 0.140 |
Why?
|
| Drug Interactions | 1 | 2017 | 289 | 0.140 |
Why?
|
| Maryland | 1 | 2016 | 77 | 0.140 |
Why?
|
| Health Status Disparities | 1 | 2020 | 326 | 0.140 |
Why?
|
| Continuity of Patient Care | 1 | 2018 | 170 | 0.140 |
Why?
|
| Administration, Intravenous | 1 | 2016 | 89 | 0.130 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 378 | 0.130 |
Why?
|
| Mice, SCID | 3 | 2010 | 238 | 0.130 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2017 | 114 | 0.130 |
Why?
|
| Convalescence | 1 | 2015 | 11 | 0.130 |
Why?
|
| Interleukin-10 | 1 | 2016 | 144 | 0.130 |
Why?
|
| Serum | 1 | 2015 | 24 | 0.130 |
Why?
|
| Influenza Vaccines | 1 | 2015 | 56 | 0.130 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 208 | 0.130 |
Why?
|
| Viral Core Proteins | 1 | 2015 | 12 | 0.120 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2016 | 87 | 0.120 |
Why?
|
| Cholesterol, LDL | 1 | 2015 | 161 | 0.120 |
Why?
|
| Hepatitis C Antibodies | 1 | 2015 | 19 | 0.120 |
Why?
|
| Erythrocytes | 1 | 2015 | 137 | 0.120 |
Why?
|
| Dyslipidemias | 1 | 2015 | 98 | 0.120 |
Why?
|
| Prevalence | 1 | 2019 | 1619 | 0.120 |
Why?
|
| Peptide Fragments | 2 | 2007 | 483 | 0.120 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 212 | 0.120 |
Why?
|
| Electronic Health Records | 1 | 2018 | 374 | 0.120 |
Why?
|
| Models, Theoretical | 1 | 2017 | 384 | 0.120 |
Why?
|
| Lymphocyte Activation | 1 | 2015 | 397 | 0.120 |
Why?
|
| Risk Factors | 3 | 2020 | 5731 | 0.110 |
Why?
|
| Pregnancy | 1 | 2019 | 2334 | 0.110 |
Why?
|
| Aged | 6 | 2018 | 14862 | 0.110 |
Why?
|
| Lipoproteins, LDL | 1 | 2015 | 343 | 0.100 |
Why?
|
| Gene Expression | 1 | 2014 | 770 | 0.100 |
Why?
|
| Gene Expression Regulation | 2 | 2016 | 1293 | 0.100 |
Why?
|
| Prospective Studies | 2 | 2016 | 3705 | 0.100 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2017 | 124 | 0.090 |
Why?
|
| Virus Internalization | 2 | 2009 | 10 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 1026 | 0.090 |
Why?
|
| Chimera | 1 | 2010 | 33 | 0.090 |
Why?
|
| Young Adult | 2 | 2018 | 5717 | 0.090 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 1 | 2009 | 1 | 0.090 |
Why?
|
| Cells, Cultured | 2 | 2005 | 2673 | 0.080 |
Why?
|
| Alcoholism | 1 | 2018 | 1109 | 0.080 |
Why?
|
| Biomarkers | 1 | 2015 | 1593 | 0.080 |
Why?
|
| Models, Animal | 1 | 2010 | 252 | 0.080 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 4848 | 0.080 |
Why?
|
| Receptors, HIV | 1 | 2007 | 5 | 0.080 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2007 | 11 | 0.080 |
Why?
|
| Receptors, Chemokine | 1 | 2007 | 26 | 0.070 |
Why?
|
| HIV Core Protein p24 | 1 | 2006 | 5 | 0.070 |
Why?
|
| Asparagine | 1 | 2006 | 15 | 0.070 |
Why?
|
| Molecular Sequence Data | 2 | 2007 | 1447 | 0.070 |
Why?
|
| Caspase 3 | 1 | 2006 | 233 | 0.070 |
Why?
|
| Reassortant Viruses | 1 | 2005 | 1 | 0.060 |
Why?
|
| Cytopathogenic Effect, Viral | 1 | 2005 | 4 | 0.060 |
Why?
|
| Microscopy, Fluorescence | 1 | 2006 | 261 | 0.060 |
Why?
|
| Cell Fusion | 1 | 2005 | 23 | 0.060 |
Why?
|
| Flow Cytometry | 1 | 2006 | 489 | 0.060 |
Why?
|
| Fluorescent Dyes | 1 | 2006 | 191 | 0.060 |
Why?
|
| Virulence | 1 | 2005 | 51 | 0.060 |
Why?
|
| Gene Products, nef | 1 | 2004 | 3 | 0.060 |
Why?
|
| nef Gene Products, Human Immunodeficiency Virus | 1 | 2004 | 5 | 0.060 |
Why?
|
| Mice | 3 | 2010 | 8474 | 0.060 |
Why?
|
| Cell Count | 1 | 2004 | 248 | 0.060 |
Why?
|
| Comorbidity | 2 | 2020 | 1426 | 0.060 |
Why?
|
| Gene Deletion | 1 | 2004 | 235 | 0.060 |
Why?
|
| Neutralization Tests | 2 | 2015 | 19 | 0.050 |
Why?
|
| Amino Acid Sequence | 1 | 2004 | 1083 | 0.050 |
Why?
|
| Protein Binding | 1 | 2005 | 1027 | 0.050 |
Why?
|
| Specialization | 1 | 2022 | 66 | 0.050 |
Why?
|
| Qualitative Research | 1 | 2022 | 369 | 0.050 |
Why?
|
| Protective Factors | 1 | 2020 | 24 | 0.040 |
Why?
|
| Animals | 4 | 2010 | 20881 | 0.040 |
Why?
|
| BRCA1 Protein | 1 | 1999 | 30 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2016 | 2358 | 0.040 |
Why?
|
| Retinoblastoma Protein | 1 | 1999 | 75 | 0.040 |
Why?
|
| Social Determinants of Health | 1 | 2020 | 96 | 0.040 |
Why?
|
| Cell Cycle | 1 | 1999 | 312 | 0.040 |
Why?
|
| Suppressor of Cytokine Signaling 1 Protein | 1 | 2017 | 4 | 0.040 |
Why?
|
| Hep G2 Cells | 1 | 2017 | 68 | 0.040 |
Why?
|
| Immunity | 1 | 2017 | 67 | 0.040 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2017 | 14 | 0.040 |
Why?
|
| Hepatic Veins | 1 | 2017 | 13 | 0.040 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2017 | 43 | 0.040 |
Why?
|
| Inosine Triphosphate | 1 | 2016 | 1 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2004 | 2550 | 0.040 |
Why?
|
| Vascular Stiffness | 1 | 2017 | 31 | 0.040 |
Why?
|
| Guanosine Triphosphate | 1 | 2016 | 65 | 0.040 |
Why?
|
| Anemia, Hemolytic | 1 | 2016 | 37 | 0.040 |
Why?
|
| Nucleotides | 1 | 2016 | 29 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 955 | 0.040 |
Why?
|
| Pressure | 1 | 2017 | 252 | 0.030 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2015 | 5 | 0.030 |
Why?
|
| Hemagglutination Inhibition Tests | 1 | 2015 | 10 | 0.030 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2015 | 13 | 0.030 |
Why?
|
| Drug Resistance, Viral | 1 | 2015 | 14 | 0.030 |
Why?
|
| RNA, Bacterial | 1 | 2015 | 30 | 0.030 |
Why?
|
| Antibodies, Neutralizing | 1 | 2015 | 46 | 0.030 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2015 | 85 | 0.030 |
Why?
|
| Bacterial Translocation | 1 | 2015 | 27 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 521 | 0.030 |
Why?
|
| Immunity, Humoral | 1 | 2015 | 42 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 2015 | 80 | 0.030 |
Why?
|
| Anti-Retroviral Agents | 1 | 2015 | 53 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 2016 | 314 | 0.030 |
Why?
|
| Myalgia | 1 | 2015 | 2 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2017 | 682 | 0.030 |
Why?
|
| Influenza, Human | 1 | 2015 | 79 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2015 | 38 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2015 | 132 | 0.030 |
Why?
|
| Cell Line | 2 | 2009 | 1752 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 1046 | 0.030 |
Why?
|
| Anemia | 1 | 2015 | 104 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2015 | 411 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2020 | 2007 | 0.030 |
Why?
|
| Cytokines | 1 | 2016 | 866 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2015 | 1553 | 0.020 |
Why?
|
| Body Weight | 1 | 2013 | 554 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 2279 | 0.020 |
Why?
|
| Inflammation | 1 | 2016 | 1030 | 0.020 |
Why?
|
| Adaptive Immunity | 1 | 2010 | 37 | 0.020 |
Why?
|
| Virus Attachment | 1 | 2009 | 3 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2010 | 138 | 0.020 |
Why?
|
| United States | 1 | 2022 | 7367 | 0.020 |
Why?
|
| Mutation | 1 | 2014 | 1213 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2009 | 204 | 0.020 |
Why?
|
| Time Factors | 1 | 2017 | 4655 | 0.020 |
Why?
|
| HIV Fusion Inhibitors | 1 | 2007 | 2 | 0.020 |
Why?
|
| Receptors, CCR5 | 1 | 2007 | 7 | 0.020 |
Why?
|
| HIV Antibodies | 1 | 2007 | 28 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2016 | 2689 | 0.020 |
Why?
|
| Base Sequence | 1 | 2007 | 1015 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2010 | 1692 | 0.020 |
Why?
|
| Adolescent | 1 | 2017 | 8912 | 0.020 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 1999 | 13 | 0.010 |
Why?
|
| Oncogene Proteins, Viral | 1 | 1999 | 21 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 1999 | 88 | 0.010 |
Why?
|
| Mutagenesis | 1 | 1999 | 60 | 0.010 |
Why?
|
| Models, Genetic | 1 | 1999 | 161 | 0.010 |
Why?
|
| Adenoviridae | 1 | 1999 | 295 | 0.010 |
Why?
|
| Plasmids | 1 | 1999 | 258 | 0.010 |
Why?
|
| Glutathione Transferase | 1 | 1999 | 166 | 0.010 |
Why?
|
| Cell Division | 1 | 1999 | 541 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1999 | 852 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 1999 | 231 | 0.010 |
Why?
|
| Transfection | 1 | 1999 | 782 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 1999 | 328 | 0.010 |
Why?
|
| Blotting, Western | 1 | 1999 | 954 | 0.010 |
Why?
|
| Phosphorylation | 1 | 1999 | 1200 | 0.010 |
Why?
|
| Fibroblasts | 1 | 1999 | 902 | 0.010 |
Why?
|